Global Public Health Leaders
JANSSEN LEADERSHIP IN GLOBAL PUBLIC HEALTH
At Janssen, we have a single overarching mission: to address and solve the most important unmet medical needs of our time.
Our commitment to global public health is an important contribution toward achieving this mission. Janssen aims to build on our strong legacy of innovation and dedication to improving global health to make a difference for patients and advance healthcare in society all over the world. Our passion and commitment run deep. We are driven to action by the plight of too many — we have heard their calls and aspire to make a positive impact on their lives.
Ultimately, we are changing how our business can deliver on the promise of our medicines, vaccines, diagnostics and services to address unmet public health needs across the world. We do this because we want to make a meaningful difference in global public health.
Wim Parys, M.D., obtained his medical degree from the Katholieke Universiteit Leuven, Belgium. He was in private practice for nine years before joining the Janssen Research Foundation in Beerse, Belgium, where he held several R&D positions and developed a drug for Alzheimer’s disease.
In 2000 Wim became the Head of Development at the biotech company Tibotec and relocated to the United States to establish Tibotec Inc., the U.S.-based subsidiary. Under his tenure, Tibotec (then acquired by Johnson & Johnson) developed and launched three innovative HIV drugs.
As Development Head of Janssen’s Infectious Diseases & Vaccines therapeutic area, he led the discovery and development of other medicines for HIV, Hepatitis C, multi-drug resistant tuberculosis and respiratory viral diseases.
In 2013 Wim became the R&D head of the newly established Global Public Health group at Janssen.
Wim Parys, M.D.
Vice President, Head of Research & Development, Global Public Health